Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/25726
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMease, Philip J.-
dc.contributor.authorKavanaugh, Arthur-
dc.contributor.authorReimold, Andreas-
dc.contributor.authorTahir, Hasan-
dc.contributor.authorRech, Juergen-
dc.contributor.authorHall, Stephen-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorPascale, Pellet-
dc.contributor.authorDelicha, Evie Marie-
dc.contributor.authorPricop, Luminata-
dc.contributor.authorMpofu, Shepard-
dc.date.accessioned2018-03-08T12:55:38Z-
dc.date.available2018-03-08T12:55:38Z-
dc.date.issued2017-
dc.identifier.citationANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470)-
dc.identifier.issn0003-4967-
dc.identifier.urihttp://hdl.handle.net/1942/25726-
dc.description.sponsorshipP. Mease Grant/research support from: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Consultant for: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, A. Kavanaugh Consultant for: Novartis, A. Reimold Grant/research support from: AbbVie, H. Tahir Speakers bureau: Novartis, Eli Lilly, and Abbvie, J. Rech Speakers bureau: Abbvie, BMS, Celgene, Fresenius, medicap, MSD, Novartis, Pfizer, and Roche, S. Hall: None declared, P. Geusens Grant/research support from: Pfizer, Abbott, Lilly, Amgen, MSD, Will, Bio Minerals and Roche, Speakers bureau: Pfizer, Abbott, Lilly, Amgen, MSD, Will, Bio Minerals and Roche, P. Pascale Shareholder of: Novartis, Employee of: Novartis, E. M. Delicha Employee of: Novartis, L. Pricop Shareholder of: Novartis, Employee of: Novartis, S. Mpofu Shareholder of: Novartis, Employee of: Novartis-
dc.language.isoen-
dc.publisherBMJ PUBLISHING GROUP-
dc.subject.othermonoclonal antibodies; Psoriatic arthritis; randomized trials and safety-
dc.titleSecukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 14-17, 2017-
local.bibliographicCitation.conferencenameAnnual European Congress of Rheumatology-
local.bibliographicCitation.conferenceplaceMadrid, SPAIN-
dc.identifier.epage953-
dc.identifier.spage952-
dc.identifier.volume76-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Mease, P. J.] Swedish Med Ctr, Seattle, WA USA. [Mease, P. J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] UC San Diego Sch Med, La Jolla, CA USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Univ Erlangen Nurnberg, Erlangen, Germany. [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E. M.; Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrSAT0470-
dc.identifier.doi10.1136/annrheumdis-2017-eular.1260-
dc.identifier.isi000413181402756-
dc.identifier.urlhttp://ard.bmj.com/content/76/Suppl_2/952-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.contributorMease, Philip J.-
item.contributorKavanaugh, Arthur-
item.contributorReimold, Andreas-
item.contributorTahir, Hasan-
item.contributorRech, Juergen-
item.contributorHall, Stephen-
item.contributorGEUSENS, Piet-
item.contributorPascale, Pellet-
item.contributorDelicha, Evie Marie-
item.contributorPricop, Luminata-
item.contributorMpofu, Shepard-
item.fullcitationMease, Philip J.; Kavanaugh, Arthur; Reimold, Andreas; Tahir, Hasan; Rech, Juergen; Hall, Stephen; GEUSENS, Piet; Pascale, Pellet; Delicha, Evie Marie; Pricop, Luminata & Mpofu, Shepard (2017) Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial. In: ANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470).-
crisitem.journal.issn0003-4967-
crisitem.journal.eissn1468-2060-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
10.1136@annrheumdis-2017-eular.1260.pdf
  Restricted Access		Published version562.59 kBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

7
checked on May 8, 2024

Page view(s)

24
checked on Sep 5, 2022

Download(s)

14
checked on Sep 5, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.